Search results
Results from the WOW.Com Content Network
Drug Manufacturer Indication Crizotinib: PF Prism: ALK-positive systemic anaplastic large cell lymphoma: Trastuzumab deruxtecan: Daiichi Sankyo: HER2-positive gastric or gastroesophageal junction adenocarcinoma, previously treated with trastuzumab: Umbralisib: TG Therapeutics: marginal zone lymphoma, previously treated with an anti-CD20-based ...
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Approved in March 2019 for CIS, RRMS and SPMS [11] [12] Ozanimod: oral. It was approved by the FDA in March 2020 with the trade name Zeposia [13] [14] [15] Ponesimod (Ponvory) Five monoclonal antibodies: Alemtuzumab (Lemtrada, Campath). [16] Natalizumab (Tysabri) Ocrelizumab (Ocrevus) [17] which is also approved for primary progressive (PPMS)
The Food and Drug Administration (FDA) approved a weight-loss drug to help sleep apnea, becoming the first drug to treat the disorder affecting millions of Americans. On Friday, the federal agency ...
U.S. regulators on Thursday approved the first drug to treat COVID-19: remdesivir, an antiviral medicine given to hospitalized patients through an IV.
The weight loss drug Zepbound, generically known as tirzepatide, is also now an approved medication to treat obstructive sleep apnea, per a Food and Drug Administration Dec. 20 press release.
Cardiac valvular disease, pulmonary hypertension, cardiac fibrosis; [3] [23] re-approved in June 2020 for the treatment of seizures associated with Dravet syndrome, under FDA orphan drug rules. Fenoterol: 1990 New Zealand Asthma mortality. [3] Feprazone: 1984 Germany, UK Cutaneous reaction, multiorgan toxicity. [3] Fipexide: 1991 France ...
In February 2020, bempedoic acid was approved for use in the United States both as a standalone drug (brand name Nexletol) [5] [17] [18] [19] and in a fixed-dose combination with ezetimibe (brand name Nexlizet). [20] The U.S. Food and Drug Administration (FDA) granted the approval of Nexletol to Esperion Therapeutics. [2] [5]